Immunic (NASDAQ:IMUX) Announces Quarterly Earnings Results

Key Points

• Immunic reported quarterly earnings of ($0.20) per share, missing the consensus estimate of ($0.18) by ($0.02).
• The stock of Immunic traded down 3.3% to $0.87, with a market capitalization of $83.56 million.
• Analysts maintain a consensus rating of "Buy" on Immunic, with an average target price of $7.50 despite recent adjustments in target prices by various firms.

Immunic (NASDAQ:IMUX - Get Free Report) posted its earnings results on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02), Zacks reports.

Immunic Trading Down 3.3%

Shares of IMUX stock traded down $0.03 during trading hours on Friday, hitting $0.87. 1,056,742 shares of the company's stock were exchanged, compared to its average volume of 1,091,344. The company has a market capitalization of $83.56 million, a PE ratio of -0.71 and a beta of 1.39. Immunic has a 12-month low of $0.56 and a 12-month high of $2.11. The business's 50 day simple moving average is $0.84 and its 200-day simple moving average is $0.97.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on IMUX shares. William Blair reiterated an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. D. Boral Capital reiterated a "buy" rating and set a $10.00 target price on shares of Immunic in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Thursday, May 1st. Finally, B. Riley reaffirmed a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a research note on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $7.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Immunic stock. Jane Street Group LLC grew its holdings in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 279.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 207,401 shares of the company's stock after acquiring an additional 152,726 shares during the quarter. Jane Street Group LLC owned 0.22% of Immunic worth $226,000 at the end of the most recent quarter. Institutional investors own 51.82% of the company's stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.